Premium
Heart Failure Association of the European Society of Cardiology update on sodium–glucose co‐transporter 2 inhibitors in heart failure
Author(s) -
Seferović Petar M.,
Fragasso Gabriele,
Petrie Mark,
Mullens Wilfried,
Ferrari Roberto,
Thum Thomas,
Bauersachs Johann,
Anker Stefan D.,
Ray Robin,
Çavuşoğlu Yuksel,
Polovina Marija,
Metra Marco,
Ambrosio Giuseppe,
Prasad Krishna,
Seferović Jelena,
Jhund Pardeep S.,
Dattilo Giuseppe,
Čelutkiene Jelena,
Piepoli Massimo,
Moura Brenda,
Chioncel Ovidiu,
Ben Gal Tuvia,
Heymans Stephane,
Jaarsma Tiny,
Hill Loreena,
Lopatin Yuri,
Lyon Alexander R.,
Ponikowski Piotr,
Lainščak Mitja,
Jankowska Ewa,
Mueller Christian,
Cosentino Francesco,
Lund Lars H.,
Filippatos Gerasimos S.,
Ruschitzka Frank,
Coats Andrew J.S.,
Rosano Giuseppe M.C.
Publication year - 2020
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1002/ejhf.2026
Subject(s) - empagliflozin , dapagliflozin , medicine , canagliflozin , heart failure , benzhydryl compounds , cardiology , diabetes mellitus , ejection fraction , type 2 diabetes , type 2 diabetes mellitus , intensive care medicine , endocrinology , organic chemistry , bisphenol a , epoxy , chemistry
The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has recently issued a position paper on the role of sodium–glucose co‐transporter 2 (SGLT2) inhibitors in heart failure (HF). The present document provides an update of the position paper, based of new clinical trial evidence. Accordingly, the following recommendations are given: • Canagliflozin, dapagliflozin empagliflozin, or ertugliflozin are recommended for the prevention of HF hospitalization in patients with type 2 diabetes mellitus and established cardiovascular disease or at high cardiovascular risk. • Dapagliflozin or empagliflozin are recommended to reduce the combined risk of HF hospitalization and cardiovascular death in symptomatic patients with HF and reduced ejection fraction already receiving guideline‐directed medical therapy regardless of the presence of type 2 diabetes mellitus.